EUCTR2014-001540-38-GB进行中(未招募)1 期
Investigation of safety and efficacy of once-daily semaglutide in obese subjects without diabetes mellitus. A 52-week, randomised, double-blind, placebo-controlled, sixteen-armed, parallel group, multi-centre, multinational trial with liraglutide 3.0 mg as active comparator
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中(未招募)
- 入组人数
- 957
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •1. Informed consent obtained before any trial-related activities. Trial-related activities are any procedures that are carried out as part of the trial, including activities to determine suitability for the trial
- •2. Male or female, age = 18 years at the time of signing inform consent
- •3. Body mass index (BMI) = 30.0 kg/m^2 at the screening visit
- •4. At least one unsuccessful weight loss attempt per investigator judgement
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 885
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 50
排除标准
- •1. A HbA1c = 6.5% at screening or diagnosed with type 1 or type 2 diabetes mellitus
- •2. Treatment with glucose lowering agent(s) within 90 days before screening
- •3. Screening calcitonin = 50 ng/L (pg/mL)
- •4. Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2
- •5. History of pancreatitis (acute or chronic)
- •6. Obesity induced by endocrine disorders (e.g. Cushing Syndrome)
- •7.Treatment with any medication within 90 days before screening that based on investigator’s judgement may cause significant weight change
- •8. Previous surgical treatment for obesity (liposuction and/or abdominoplasty performed > 1 year before screening is allowed)
- •9. History of major depressive disorder within 2 years before randomisation
- •10. Any lifetime history of a suicidal attempt
- •11. Female who is pregnant, breast-feeding or intends to become pregnant or is of childbearing potential and not using an adequate contraceptive method (adequate contraceptive measures as required by local regulation or practice)
研究者
相似试验
进行中(未招募)
1 期
Investigation of safety and efficacy of once-daily semaglutide in obese subjects without diabetes mellitusMedDRA version: 18.1Level: PTClassification code 10029883Term: ObesitySystem Organ Class: 10027433 - Metabolism and nutrition disordersObesityEUCTR2014-001540-38-BEovo Nordisk A/S935
进行中(未招募)
1 期
Investigation of safety and efficacy of once-daily semaglutide in obese subjects without diabetes mellitusObesityEUCTR2014-001540-38-DEovo Nordisk A/S935
进行中(未招募)
1 期
Efficacy and safety of delgocitinib cream in discoid lupus erythematosus.Discoid lupus erythematosusMedDRA version: 20.0Level: LLTClassification code 10013072Term: Discoid lupus erythematosusSystem Organ Class: 100000004858EUCTR2018-003615-22-FREO Pharma A/S45
进行中(未招募)
1 期
Efficacy and safety of delgocitinib cream in discoid lupus erythematosus.MedDRA version: 21.1Level: LLTClassification code 10013072Term: Discoid lupus erythematosusSystem Organ Class: 100000004858Discoid lupus erythematosusEUCTR2018-003615-22-DEEO Pharma A/S45
进行中(未招募)
1 期
Efficacy and safety of delgocitinib cream in discoid lupus erythematosus.Discoid lupus erythematosusMedDRA version: 21.1Level: LLTClassification code 10013072Term: Discoid lupus erythematosusSystem Organ Class: 100000004858EUCTR2018-003615-22-DKEO Pharma A/S45
